|

Liver Disease Clinical Trials in Memphis, TN

18 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 2<1 mi
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment—<1 mi
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisPhase 2<1 mi
Indocyanine Green (ICG) Guided Tumor ResectionPhase 1<1 mi
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsPhase 1/2<1 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—<1 mi
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsPhase 1/2<1 mi
Molecular Analysis Of Solid Tumors—<1 mi
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPhase 3<1 mi
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )Phase 314 mi
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisPhase 214 mi
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)Phase 214 mi
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCPhase 214 mi
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisPhase 315 mi
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisPhase 315 mi
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHPhase 315 mi
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Phase 315 mi
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Phase 315 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.